KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Effect of robotic versus open pancreaticoduodenectomy on postoperative length of hospital stay and complications for pancreatic head or periampullary tumours: a multicentre, open-label randomised controlled trial. PMID 38428441 · Lancet Gastroenterol Hepatol · 2024-May The trial is a randomized oncology study, but it is ineligible because it lacks a drug intervention (it is a surgical technique comparison) and lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Predicting the Survival Benefit of Radiotherapy in Elderly Breast Cancer Patients: A Population-Based Analysis. PMID 38428261 · J Surg Res · 2024-May The record describes a retrospective, population-based analysis from SEER data, not a randomized trial. While the publication type includes 'Randomized Controlled Trial', the abstract clearly indicates the 'randomization' was for splitting data into training/validation cohorts for statistical modeling, not for assigning treatments. Furthermore, the intervention is radiotherapy, which is not a drug-containing intervention. Therefore, it does not meet the criteria for a Phase III/IIIb or Phase II/III randomized trial with a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up. PMID 38418610 · Leukemia · 2024-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H L B
旧查询独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. PMID 38402342 · Br J Cancer · 2024-May The record describes a pooled analysis of individual patient data from multiple randomized trials, not an original formal-result report of a single Phase III/IIIb or Phase II/III trial. While it meets criteria for oncology, human, randomized, time-to-event, and drug intervention, it fails the 'original_result' criterion. The phase of the included trials is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Improvement of fatigue in generalised myasthenia gravis with zilucoplan. PMID 38400914 · J Neurol · 2024-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Regional variation in cause of death in patients with type 2 diabetes: Insights from EXSCEL. PMID 38395292 · Am Heart J · 2024-May The record describes an analysis of cause-specific mortality in the EXSCEL trial for type 2 diabetes, which is not an oncology study. The primary condition is type 2 diabetes and cardiovascular risk, not a human malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery. PMID 38390818 · Future Oncol · 2024-May Meets all inclusion criteria: oncology, human, randomized, phase 3, time-to-event efficacy endpoint (RFS/DMFS), drug intervention, and original result report (lay summary of primary trial results).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison. PMID 38383713 · Bone Marrow Transplant · 2024-May The record describes an original, randomized, comparative study (MC-FludT.14/L Trial II) with primary time-to-event efficacy endpoints (OS, NRM, relapse incidence) for drug-containing conditioning regimens in oncology. However, the explicit clinical trial phase (Phase III/IIIb or Phase II/III) is not confirmed in the provided metadata (e.g., title, abstract, publication types), which is required for eligibility under the specified criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Long-term oncological outcomes of 3D versus 2D laparoscopic gastrectomy for gastric cancer: a randomized clinical trial. PMID 38379100 · Gastric Cancer · 2024-May 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE. PMID 38347093 · Br J Cancer · 2024-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies. PMID 38311180 · Value Health · 2024-May While the record meets criteria for oncology, human, randomized, Phase III, and drug intervention, it lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis. The study's focus is on a quality-of-life/symptom endpoint, which falls under a secondary report type and is not eligible for the requested cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of different follow-up regimens on health-related quality of life and costs in endometrial cancer patients: Results from the TOTEM randomized trial. PMID 38309033 · Gynecol Oncol · 2024-May The record is an oncology, human, randomized trial with original results, but it does not meet the required criteria for inclusion. It lacks a drug-containing intervention (it compares follow-up regimens, not drugs) and does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The phase is also not clearly established as Phase III/IIIb or Phase II/III from the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial. PMID 38291268 · Breast Cancer Res Treat · 2024-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
CT venography combined with ultrasound-guided minimally invasive treatment for recurrent varicose veins: a pilot paired-design clinical trial. PMID 38290939 · Clin Radiol · 2024-May The study is a randomized clinical trial for recurrent varicose veins (non-oncology) and does not involve a drug intervention (only imaging and minimally invasive procedures). Therefore, it does not meet the core eligibility criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use-A Prospective Real-Life Study. PMID 38286884 · Ann Surg Oncol · 2024-May The record is an original, prospective observational study on real-world patterns of adjuvant therapy omission and use after pancreatic cancer surgery. It is not a randomized trial, is not Phase III, and does not report any time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or hazard ratio data. The analysis is non-comparative and focuses on predictors of treatment omission/delay, not treatment efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial. PMID 38280052 · Breast Cancer Res Treat · 2024-May The study is a pilot/feasibility trial, not a definitive Phase III/IIIb or Phase II/III randomized trial. Its primary endpoint is change in a patient-reported outcome (FACT-ES), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. No Kaplan-Meier or hazard ratio data is reported or implied for such endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials. PMID 38279016 · Breast Cancer Res Treat · 2024-May The study is an oncology randomized controlled trial with a drug intervention (metformin) and reports original results. However, it is not a Phase III/IIIb or Phase II/III trial (phase not specified), and the primary endpoint is not a time-to-event efficacy endpoint (e.g., OS, PFS) but rather changes in biomarkers (adipokines, hormones). The report type is 'secondary' as it is a biomarker analysis from a pooled trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-Caregiver Dyads & End-of-Life Care: Caregiver Personality Disrupts Gender-Based Norms. PMID 38278189 · J Pain Symptom Manage · 2024-May The record is a secondary analysis from a randomized trial in advanced cancer, but it does not meet key eligibility criteria: it is not a definitive Phase III trial, the endpoints are not time-to-event efficacy measures (they are counts/proportions of care utilization), and the analysis does not evaluate a drug intervention as the primary experimental factor.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). PMID 38243037 · Gastric Cancer · 2024-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Novel alternative tools for metastatic pheochromocytomas/paragangliomas prediction. PMID 38206552 · J Endocrinol Invest · 2024-May The study is a retrospective, randomized (data split) analysis of pheochromocytomas/paragangliomas, an oncology topic in humans with a time-to-event endpoint (metastasis-free survival). However, it does not report a Phase III/IIIb or Phase II/III randomized trial. It is a prognostic model development study without any drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications': [Annals of Oncology 34 (2023) p693-702]. PMID 38195363 · Ann Oncol · 2024-May The record is a corrigendum to a published erratum for a Phase III randomized trial of atezolizumab in NSCLC. However, the abstract is empty, and the metadata does not confirm the presence of a time-to-event efficacy endpoint (OS, PFS, etc.) or a Kaplan-Meier plot/Hazard Ratio. Therefore, eligibility cannot be determined.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network Meta-Analysis. PMID 38116697 · Arthritis Rheumatol · 2024-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparison of Microwave and Radiofrequency Ablation for the Treatment of Small- and Medium-Sized Hepatocellular Carcinomas in a Prospective Randomized Trial. PMID 38065541 · Rofo · 2024-May Eligible for oncology, human, randomized, time-to-event efficacy, and original result criteria. Excluded because the intervention is a non-drug-only procedure (microwave vs. radiofrequency ablation), not a drug-containing intervention, and the report does not explicitly establish a Phase III/IIIb or Phase II/III trial phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Braided-type stent versus laser-cut-type stent for patients with unresectable distal malignant biliary obstruction: a randomized controlled trial. PMID 38065510 · Gastrointest Endosc · 2024-May 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Impact of peritoneal vaginoplasty combined with radical hysterectomy on the quality of sexual life for patients with early-stage cervical cancer: trial protocol for a multi-center superiority randomized controlled trial. PMID 38037548 · J Gynecol Oncol · 2024-May 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparison of covered self-expandable metallic stents with 12-mm and 10-mm diameters for unresectable malignant distal biliary obstructions: a prospective randomized trial. PMID 38000479 · Gastrointest Endosc · 2024-May The trial is randomized and in oncology patients with drug intervention (chemotherapy) as a covariate. However, the primary endpoint is 'time to recurrent biliary obstruction' (a stent patency measure), not a standard cancer efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint in the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA). PMID 37586908 · Dig Liver Dis · 2024-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast Cancer: A Randomized Clinical Study. PMID 38612725 · Int J Mol Sci · 2024-Mar-31 The study is a randomized trial in human breast cancer with OS and DFS endpoints, but the record does not establish that it is a Phase III/IIIb or Phase II/III trial, and it does not clearly establish a drug-containing intervention. The abstract mentions 'neoadjuvant therapy (NAC)' but does not specify a drug; it could be chemotherapy, which is a drug intervention, but the metadata does not confirm this. The phase is not explicitly stated in the provided information. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial. PMID 38450721 · Eur J Endocrinol · 2024-Mar-30 The record describes a randomized trial in humans with an oncology-related condition (craniopharyngioma) and a drug intervention (exenatide). However, it is excluded because the trial does not meet the required criteria: it lacks a Phase III/IIIb or Phase II/III designation (no phase is explicitly stated), and the primary efficacy endpoint is mean change in body weight at 26 weeks, not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, or analysis using Kaplan-Meier or HR.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial. PMID 38553680 · BMC Cancer · 2024-Mar-29 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer. PMID 38611000 · Cancers (Basel) · 2024-Mar-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Analgesic Efficacy and Safety of Intrathecal Morphine or Intercostal Levobupivacaine in Lung Cancer Patients after Major Lung Resection Surgery by Videothoracoscopy: A Prospective Randomized Controlled Trial. PMID 38610735 · J Clin Med · 2024-Mar-28 The record is a randomized trial comparing analgesic techniques for postoperative pain control in lung cancer patients undergoing surgery. It meets criteria for oncology, human, randomized, and drug intervention. However, it is excluded because it lacks a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, or KM curve). The primary outcomes are pain scores and morphine consumption, which are not time-to-event measures. Additionally, the trial phase is not specified as Phase III or IIIb; it is an analgesic efficacy study within a surgical context, not a definitive treatment trial for the malignancy itself.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Short-Term Creatine Supplementation on Muscular Performance among Breast Cancer Survivors. PMID 38613014 · Nutrients · 2024-Mar-27 The study is a randomized, placebo-controlled trial in breast cancer survivors, but it does not meet key eligibility criteria: the trial phase is not specified as Phase III/IIIb or II/III, the intervention is creatine supplementation (a dietary supplement, not a cancer drug), and the primary endpoint is muscular performance (strength, power) rather than a time-to-event efficacy endpoint such as overall survival or progression-free survival.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A WeChat-based nursing intervention program improves the postoperative rehabilitation of breast cancer patients: results from a randomized controlled trial. PMID 38601277 · Gland Surg · 2024-Mar-27 The record describes a randomized nursing intervention trial in breast cancer patients. It is oncology, human, randomized, and an original result. However, it is excluded because: (1) the intervention is non-drug (a nursing program), and (2) the endpoints are patient-reported outcomes and quality-of-life measures, not time-to-event efficacy endpoints like OS/PFS/DFS or any Kaplan-Meier/HR analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. PMID 38538574 · Nat Commun · 2024-Mar-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Clinical statistical analysis plan for the ACCURE trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicentre trial. PMID 38532488 · Trials · 2024-Mar-26 The trial is for ulcerative colitis (inflammatory bowel disease), not a malignant neoplasm (cancer). It is a protocol/statistical analysis plan without results. The intervention is surgical (appendectomy), not a drug intervention. The primary outcome is a 1-year relapse rate (categorical), not a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cardiac troponin I as predictor for cardiac and other mortality in the German randomized lung cancer screening trial (LUSI). PMID 38531926 · Sci Rep · 2024-Mar-26 The study is a randomized analysis from the LUSI trial (a lung cancer screening trial), but it is a biomarker/prognostic analysis of cardiac mortality risk, not a report of a drug-containing intervention's efficacy. It lacks a drug arm and is not a Phase III trial report evaluating a drug intervention's effect on a cancer endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of natural killer cells injection combined with XELOX chemotherapy in postoperative patients with stage III colorectal cancer in China: a prospective randomised controlled clinical trial study protocol. PMID 38531576 · BMJ Open · 2024-Mar-25 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial. PMID 38528445 · BMC Cancer · 2024-Mar-25 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial. PMID 38519525 · Nat Commun · 2024-Mar-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical efficacy analysis of surgical treatment for spinal metastasis under the multidisciplinary team using the NOMS decision system combined with the revised Tokuhashi scoring system: a randomized controlled study. PMID 38515197 · J Orthop Surg Res · 2024-Mar-21 The study is an oncology randomized trial with original results but does not meet the core eligibility criteria: it lacks a drug-containing intervention and a primary time-to-event efficacy endpoint. It focuses on surgical decision-making and clinical outcomes like complications and quality of life.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases. PMID 38515096 · BMC Cancer · 2024-Mar-21 The study is an oncology analysis on human patients with a time-to-event endpoint and a drug intervention, but it is not a Phase III/IIIb or Phase II/III randomized trial report. It is a retrospective predictive modeling study using data from a cohort, not a formal report of a randomized trial's primary or secondary efficacy results. The phase is not established in the metadata, and the design is not a prospective randomized trial comparing drug interventions.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effectiveness of Preoperative Immunonutrition in Improving Surgical Outcomes after Radical Cystectomy for Bladder Cancer: Study Protocol for a Multicentre, Open-Label, Randomised Trial (INu-RC). PMID 38540660 · Healthcare (Basel) · 2024-Mar-20 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. PMID 38252901 · J Clin Oncol · 2024-Mar-20 The report is a secondary endpoint analysis of a drug trial in oncology, but the required Phase III/IIIb or Phase II/III evidence is not explicitly confirmed in the provided metadata. Therefore, it cannot be marked as definitively eligible under the strict inclusion criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. PMID 38402886 · Lancet · 2024-Mar-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations. PMID 38489927 · J Natl Compr Canc Netw · 2024-Mar-15 The record describes a randomized trial of patient navigation for lung cancer screening, which is oncology-related and human, but it lacks a drug intervention and a time-to-event efficacy endpoint. The primary endpoint is completion of screening steps, not a survival or progression outcome. Therefore, it does not meet the eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study. PMID 38488934 · Langenbecks Arch Surg · 2024-Mar-15 The study is a randomized, oncology trial with human patients and time-to-event endpoints. However, it is ineligible because it does not meet the required evidence level (Phase III/IIIb or Phase II/III) and, crucially, lacks a drug-containing intervention. The comparison is between radiotherapy (non-drug) and TACE (a procedure, not a systemic drug therapy). Therefore, it fails two core eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5. PMID 37933882 · Cancer · 2024-Mar-15 The record is a pooled analysis of multiple protocols, not a formal result report of a single Phase III/IIIb or Phase II/III randomized trial. While it contains oncology, human, randomized, drug intervention, and time-to-event components, the phase is not explicitly confirmed as definitive (Phase III/IIIb or II/III) for the primary trial, and the report is an integrated analysis rather than a primary trial result.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Physician- and Patient-Reported Outcomes of the MC1635 Phase 3 Trial of Ultrahypofractionated Versus Moderately Hypofractionated Adjuvant Radiation Therapy After Breast-Conserving Surgery. PMID 37914139 · Int J Radiat Oncol Biol Phys · 2024-Mar-15 This is a Phase 3 randomized trial of adjuvant radiotherapy (a non-drug intervention) for breast cancer, with outcomes focusing on physician/patient-reported toxicities, cosmesis, and quality of life. It does not meet the requirement for a drug-containing intervention or a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial. PMID 37871887 · Int J Radiat Oncol Biol Phys · 2024-Mar-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -